<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Tetanus</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Tetanus</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Tetanus</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Louise Thwaites, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Daniel J Sexton, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer Mitty, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jun 10, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Tetanus is a nervous system disorder characterized by muscle spasms that is caused by the toxin-producing anaerobe <em>Clostridium tetani</em>, which is found in the soil. The clinical features of tetanus and its relationship to traumatic injuries were well known among the ancient Greeks and Egyptians and to many clinicians before the introduction of vaccination with tetanus toxoid in the 1940s. The term "lockjaw" (or trismus) lives in modern parlance as a reminder of one of the cardinal features of tetanus: intense, painful spasms of the masseter muscles, and an inability to open the mouth.</p><p>Tetanus can present in one of four clinical patterns:</p><p class="bulletIndent1"><span class="glyph">●</span>Generalized</p><p class="bulletIndent1"><span class="glyph">●</span>Local</p><p class="bulletIndent1"><span class="glyph">●</span>Cephalic</p><p class="bulletIndent1"><span class="glyph">●</span>Neonatal</p><p></p><p>Although tetanus is now rare in resource-rich settings, the disease remains a threat to all unvaccinated people, particularly in resource-limited countries. Since <em>C. tetani</em> spores cannot be eliminated from the environment, immunization and proper treatment of wounds and traumatic injuries are crucial for tetanus prevention. The epidemiology, pathogenesis, clinical features, diagnosis, and management of tetanus will be reviewed here. The principles of prevention of tetanus and management of tetanus-prone wounds are discussed separately. (See  <a class="medical medical_review" href="/d/html/3897.html" rel="external">"Tetanus-diphtheria toxoid vaccination in adults"</a> and  <a class="medical medical_review" href="/d/html/2844.html" rel="external">"Diphtheria, tetanus, and pertussis immunization in children 6 weeks through 6 years of age"</a> and  <a class="medical medical_review" href="/d/html/2838.html" rel="external">"Diphtheria, tetanus, and pertussis immunization in children 7 through 18 years of age"</a> and  <a class="medical medical_review" href="/d/html/7661.html" rel="external">"Infectious complications of puncture wounds"</a> and  <a class="medical medical_review" href="/d/html/7671.html" rel="external">"Animal bites (dogs, cats, and other mammals): Evaluation and management"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">EPIDEMIOLOGY</span></p><p class="headingAnchor" id="H3"><span class="h2">Resource-rich countries</span><span class="headingEndMark"> — </span>Because of almost universal vaccination of children with tetanus toxoid in resource-rich countries, the incidence of tetanus in these regions has dropped dramatically and steadily since 1940. During the period between 2009 and 2017, the United States Centers for Disease Control and Prevention (CDC) reported that there were 264 cases of tetanus in the United States [<a href="#rid1">1</a>]. Sixty cases (23 percent) were in individuals ≥65 years of age and only 36 (13 percent) were individuals younger than 20 years. Twelve percent of patients with tetanus had diabetes mellitus and another 8 percent of patients were injection drug users. The case-fatality rate was 7.2 percent overall and all deaths occurred in individuals ≥55 years of age. In 2019, 26 cases of tetanus and 2 deaths were reported in the United States through the national tetanus surveillance system [<a href="#rid2">2</a>].</p><p>Most patients with tetanus lack a history of receipt of a full series of tetanus toxoid immunization and receive inadequate prophylaxis following a wound [<a href="#rid3">3-5</a>]. Approximately three-fourths of patients who acquired tetanus in the United States between 2001 and 2008 recalled an acute injury prior to the onset of their symptoms, but approximately two-thirds of these individuals did not seek medical care [<a href="#rid3">3</a>]. Among 51 patients who sought care for an acute wound and had a sufficiently thorough surveillance report to allow evaluation, 49 (96 percent) did not receive adequate tetanus toxoid prophylaxis or tetanus toxoid prophylaxis plus <a class="drug drug_general" data-topicid="9983" href="/d/drug information/9983.html" rel="external">tetanus immune globulin</a> [<a href="#rid3">3</a>]. However, occasional patients with pre-existing antitetanus antibodies (as measured by guinea pig or mouse protection assays) have developed tetanus [<a href="#rid6">6</a>]. (See  <a class="medical medical_review" href="/d/html/3897.html" rel="external">"Tetanus-diphtheria toxoid vaccination in adults"</a> and  <a class="medical medical_review" href="/d/html/2844.html" rel="external">"Diphtheria, tetanus, and pertussis immunization in children 6 weeks through 6 years of age", section on 'Schedules'</a> and  <a class="medical medical_review" href="/d/html/2838.html" rel="external">"Diphtheria, tetanus, and pertussis immunization in children 7 through 18 years of age", section on 'Indications'</a>.)</p><p>Unlike in resource-limited nations, neonatal tetanus is extremely rare in the United States. Only two cases of neonatal tetanus were reported between 2009 and 2017 [<a href="#rid1">1</a>]. </p><p>The annual incidence of tetanus in other resource-rich countries is also low and declining due to vaccination programs. In England and Wales, for example, the annual incidence was 0.1 cases/million population, with almost all cases occurring in those born before the introduction of routine childhood vaccination [<a href="#rid7">7,8</a>]. Nevertheless, a study of hospital records between 2001 and 2014 estimated that approximately 88 percent of cases in England were under-reported [<a href="#rid9">9</a>]. Italy reported the highest number of cases among countries in Europe, but the annual incidence decreased from 0.5 to 0.02 per 100,000 between the 1970s and 2018 [<a href="#rid10">10</a>]. The overall case fatality rate of the 49 European cases with known outcome was 26.5 percent.</p><p>Despite the low rate of clinical disease in resource-rich countries, many adults are inadequately vaccinated against tetanus. In the serologic survey cited above in the United States between 1988 and 1994, protective levels of antitetanus antibody (&gt;0.15 international units/mL) were present in 72 percent of individuals ≥6 years of age but only 31 percent of adults over the age of 70 [<a href="#rid11">11</a>]. Not surprisingly, protective antibody levels are more likely in adults with a history of military service, higher levels of education, and higher incomes [<a href="#rid12">12</a>].</p><p class="headingAnchor" id="H4"><span class="h2">Resource-limited countries</span><span class="headingEndMark"> — </span>In contrast with resource-rich nations where tetanus is rare, tetanus remains endemic in resource-limited settings, and the incidence often increases following natural disasters such as earthquakes and tsunamis [<a href="#rid13">13</a>]. According to data from the global burden of disease survey, an estimated 48,000 to 80,000 deaths occurred from tetanus worldwide in 2016 [<a href="#rid14">14</a>]. True disease incidence is unknown, since tetanus is not a notifiable disease in most countries. National hospital admissions data in Uganda revealed a total of 4750 cases of tetanus in 2014 (125 cases per million population) [<a href="#rid15">15</a>]. The majority of these cases were in individuals &gt;5 years of age.</p><p>Case-fatality rates in many resource-limited settings remain high and have not changed significantly in the past several decades. The pooled fatality rate of 3043 adult African patients reported in 27 studies was 43 percent (95% CI 37 to 50 percent) [<a href="#rid16">16</a>]. The high fatality rate likely reflects the fact that mechanical ventilation was often not accessible in many of the included medical facilities. </p><p>Neonatal tetanus, which the World Health Organization targeted for elimination by 1995, accounted for approximately 34,000 deaths in 2015 [<a href="#rid17">17</a>]. While this represents a decrease in mortality of 96 percent compared with 1988 [<a href="#rid17">17</a>], as of 2020, 12 countries had still not eliminated maternal and neonatal tetanus [<a href="#rid17">17</a>]. (See <a class="local">'Neonatal tetanus'</a> below.)</p><p class="headingAnchor" id="H5"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>Tetanus occurs when spores of <em>C. tetani</em>, an obligate anaerobe normally present in the gut of mammals and widely found in soil, gains access to damaged human tissue. After inoculation, <em>C. tetani</em> transforms into a vegetative rod-shaped bacterium and produces the metalloprotease tetanus toxin (also known as tetanospasmin).</p><p>After reaching the spinal cord and brainstem via retrograde axonal transport within the motor neuron, tetanus toxin is secreted and enters adjacent inhibitory interneurons, where it blocks neurotransmission by its cleaving action on the membrane proteins involved in neuroexocytosis [<a href="#rid18">18-21</a>]. The net effect is inactivation of inhibitory neurotransmission that normally modulates anterior horn cells and muscle contraction. This loss of inhibition (ie, disinhibition) of anterior horn cells and autonomic neurons results in increased muscle tone, painful spasms, and widespread autonomic instability.</p><p>Muscular rigidity in tetanus occurs though a complex mechanism that involves an increase in the resting firing rate of disinhibited motor neurons and lack of inhibition of reflex motor responses to afferent sensory stimuli [<a href="#rid22">22</a>]. Lack of neural control of adrenal release of catecholamines induced by tetanus toxin produces a hypersympathetic state that manifests as sweating, tachycardia, and hypertension. (See <a class="local">'Generalized tetanus'</a> below.)</p><p>Tetanus toxin-induced effects on anterior horns cells, the brainstem, and autonomic neurons are long lasting because recovery requires the growth of new axonal nerve terminals. (See <a class="local">'Duration of illness'</a> below.)</p><p>The mechanisms of binding to and inhibition of neural cells are related to specific portions of the tetanus toxin molecule. Tetanus toxin is produced initially as an inactive polypeptide chain by actively growing organisms. This synthesis is controlled by genes located in an intracellular plasmid.</p><p>After the toxin is released, it is activated by bacterial or tissue proteases into its active form, which contains a heavy chain necessary for binding and entry into neurons and a light chain responsible for its toxic properties [<a href="#rid21">21-24</a>]. Heavy chains are further cleaved by pepsins into specific fragments, which individually mediate binding to specific types of neural cells. Presynaptic inhibition of neurotransmitter release is mediated via light chains.</p><p>Tetanolysin is another toxin produced by <em>C. tetani</em> during its early growth phase. It has hemolytic properties and causes membrane damage in other cells, but its role in clinical tetanus is uncertain.</p><p class="headingAnchor" id="H6"><span class="h2">Predisposing factors</span><span class="headingEndMark"> — </span>Because <em>C. tetani</em> will not grow in healthy tissues, a convergence of factors must be present in order for tetanus toxin to be elaborated in the human host. This combination of factors usually includes absence of antibodies (ie, from inadequate vaccination) plus two or more of the following:</p><p class="bulletIndent1"><span class="glyph">●</span>A penetrating injury resulting in the inoculation of <em>C. tetani</em> spores</p><p class="bulletIndent1"><span class="glyph">●</span>Coinfection with other bacteria</p><p class="bulletIndent1"><span class="glyph">●</span>Devitalized tissue</p><p class="bulletIndent1"><span class="glyph">●</span>A foreign body</p><p class="bulletIndent1"><span class="glyph">●</span>Localized ischemia</p><p></p><p>The above factors explain why tetanus-prone injuries include splinters and other puncture wounds, gunshot wounds, compound fractures, burns, and unsterile intramuscular or subcutaneous injections (that often occur in injection drug users). These predisposing factors can also explain why tetanus can develop in unusual clinical settings such as in:</p><p class="bulletIndent1"><span class="glyph">●</span>Neonates (due to infection of the umbilical stump)</p><p class="bulletIndent1"><span class="glyph">●</span>Obstetric patients (after septic abortions)</p><p class="bulletIndent1"><span class="glyph">●</span>Postsurgical patients (with necrotic infections involving bowel flora)</p><p class="bulletIndent1"><span class="glyph">●</span>Adolescents and adults undergoing male circumcision in sub-Saharan Africa [<a href="#rid25">25</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with dental infections</p><p class="bulletIndent1"><span class="glyph">●</span>Diabetic patients with infected extremity ulcers</p><p class="bulletIndent1"><span class="glyph">●</span>Patients who inject illicit and/or contaminated drugs [<a href="#rid26">26</a>]</p><p></p><p class="headingAnchor" id="H7"><span class="h2">Tetanus in patients without an identifiable cause</span><span class="headingEndMark"> — </span>An identifiable antecedent cause for tetanus is obvious in most patients presenting with tetanus, but no cause can be identified in up to a quarter of patients with classic signs and symptoms of tetanus. Presumably, minor unnoticed abrasions or skin injuries are responsible for most or all of these "cryptogenic" cases. Tetanus has occurred rarely in patients who have received a timely and correct series of tetanus immunizations [<a href="#rid27">27</a>].</p><p class="headingAnchor" id="H8"><span class="h1">CLINICAL FEATURES</span></p><p class="headingAnchor" id="H9"><span class="h2">Incubation period</span><span class="headingEndMark"> — </span>The incubation period of tetanus is approximately 8 days but ranges from 3 to 21 days [<a href="#rid28">28</a>]. The incubation period is typically shorter in neonatal tetanus than in non-neonatal tetanus [<a href="#rid24">24</a>]. (See <a class="local">'Neonatal tetanus'</a> below.)</p><p class="headingAnchor" id="H10"><span class="h2">Generalized tetanus</span><span class="headingEndMark"> — </span>The most common and severe clinical form of tetanus is generalized tetanus. The presenting symptom in more than 80 percent of such patients is trismus (lockjaw), although patients with generalized tetanus sometimes present initially with cephalic or localized tetanus. Patients with generalized tetanus typically have symptoms of autonomic overactivity that may manifest in the early phases as sweating and tachycardia. In later phases of illness, profuse sweating, cardiac arrhythmias, labile hypertension or hypotension, and fever are often present.</p><p>Patients with generalized tetanus characteristically have tonic contraction of their skeletal muscles and intermittent intense muscular spasms. Since patients with tetanus have no impairment of consciousness or awareness, both the tonic contractions and spasms are intensely painful. Tetanic spasms may be triggered by loud noises or other sensory stimuli such as physical contact or light. Tonic and periodic spastic muscular contractions are responsible for most of the classic clinical findings of tetanus such as:</p><p class="bulletIndent1"><span class="glyph">●</span>Stiff neck</p><p class="bulletIndent1"><span class="glyph">●</span>Opisthotonus</p><p class="bulletIndent1"><span class="glyph">●</span>Risus sardonicus (sardonic smile)</p><p class="bulletIndent1"><span class="glyph">●</span>A board-like rigid abdomen</p><p class="bulletIndent1"><span class="glyph">●</span>Periods of apnea and/or upper airway obstruction due to vise-like contraction of the thoracic muscles and/or glottal or pharyngeal muscle contraction, respectively</p><p class="bulletIndent1"><span class="glyph">●</span>Dysphagia</p><p></p><p>During generalized tetanic spasms, patients characteristically clench their fists, arch their back, and flex and abduct their arms while extending their legs, often becoming apneic during these dramatic postures.</p><p class="headingAnchor" id="H11"><span class="h2">Local tetanus</span><span class="headingEndMark"> — </span>Rarely, tetanus presents with tonic and spastic muscle contractions in one extremity or body region. Local tetanus often but not invariably evolves into generalized tetanus. Diagnosis in local tetanus can be difficult. For example, rarely patients with early tetanus may develop board-like abdominal rigidity that mimics an acute surgical abdomen.</p><p class="headingAnchor" id="H12"><span class="h2">Cephalic tetanus</span><span class="headingEndMark"> — </span>Patients with injuries to the head or neck may present with cephalic tetanus, involving initially only cranial nerves. Like other forms of local tetanus, patients with cephalic tetanus often subsequently develop generalized tetanus. Prior to the appearance of the typical features of generalized tetanus, patients with cephalic tetanus may manifest confusing clinical findings including dysphagia, trismus, and focal cranial neuropathies that can lead to a misdiagnosis of stroke [<a href="#rid29">29</a>]. The facial nerve is most commonly in cephalic tetanus [<a href="#rid30">30</a>], but involvement of cranial nerves VI, III, IV, and XII may also occur either alone or in combination with others.</p><p class="headingAnchor" id="H13"><span class="h2">Neonatal tetanus</span><span class="headingEndMark"> — </span>Neonatal tetanus occurs as a result of the failure to use aseptic techniques in managing the umbilical stump in offspring of mothers who are poorly immunized. The application of unconventional substances to the umbilical stump (eg, ghee or clarified butter, juices, and cow dung) have been implicated as common cultural practices that contribute to neonatal tetanus [<a href="#rid31">31</a>]. Neonatal tetanus can also result from unclean hands and instruments or contamination by dirt, straw, or other nonsterile materials in the delivery field.</p><p>Neonatal tetanus typically occurs in infants 5 to 7 days following birth (range 3 to 24 days) [<a href="#rid24">24</a>]. The onset of illness is typically more rapid in neonatal tetanus than in older individuals and may progress over hours rather than days, probably because axonal length is proportionately shorter in infants [<a href="#rid32">32</a>].</p><p>Neonatal tetanus presents with refusal to feed and difficulty opening the mouth due to trismus in an infant previously able to feed and cry normally [<a href="#rid24">24</a>]. Sucking then stops and facial muscles spasm, which may result in risus sardonicus (sardonic smile). The hands are often clenched, the feet become dorsiflexed, and muscle tone increases. As the disease progresses, neonates become rigid and opisthotonus (spasm of spinal extensors) develops.</p><p class="headingAnchor" id="H14"><span class="h2">Severity of illness</span><span class="headingEndMark"> — </span>The severity and frequency of the clinical features of tetanus may vary from case to case, depending upon the amount of tetanus toxin that reaches the central nervous system. Symptoms and signs may progress for up to two weeks after the disease onset. The severity is related to the incubation period of the illness and the interval from the onset of symptoms to the appearance of spasms [<a href="#rid33">33</a>]; the longer the interval, the milder the clinical features of tetanus. More severe illness is seen in those with deep penetrating wounds [<a href="#rid33">33</a>]. </p><p class="headingAnchor" id="H15"><span class="h2">Duration of illness</span><span class="headingEndMark"> — </span>Tetanus toxin-induced effects are long lasting because recovery is believed to require the growth of new axonal nerve terminals. The usual duration of clinical tetanus is four to six weeks.</p><p class="headingAnchor" id="H16"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of tetanus is usually obvious and can generally be made based upon typical clinical findings outlined above. Tetanus should especially be suspected when there is a history of an antecedent tetanus-prone injury and a history of inadequate immunization for tetanus. However, tetanus can sometimes be confused with other processes, as discussed in the following section.</p><p class="headingAnchor" id="H1917381"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>Tetanus can sometimes be confused with the following mimics.</p><p class="headingAnchor" id="H17"><span class="h2">Drug-induced dystonias such as those due to phenothiazines</span><span class="headingEndMark"> — </span>Drug-induced dystonias often produce pronounced deviation of the eyes, writhing movements of the head and neck, and an absence of tonic muscular contraction between spasms. By contrast, tetanus does not produce eye deviations, and the muscles are characteristic tonically contracted between spasms. Finally, administration of an anticholinergic agent such as <a class="drug drug_general" data-topicid="9106" href="/d/drug information/9106.html" rel="external">benztropine</a> mesylate will usually immediately reverse the spasms seen in drug-induced dystonias. Such therapy has no effect on patients with tetanus.</p><p class="headingAnchor" id="H18"><span class="h2">Trismus due to dental infection</span><span class="headingEndMark"> — </span>Dental infections may produce trismus that may rarely be confused with cephalic forms of tetanus. However, the presence of an obvious dental abscess and the lack of progression or superimposed spasms usually make the distinction between the two diseases apparent after initial evaluation and/or a period of observation. (See  <a class="medical medical_review" href="/d/html/3415.html" rel="external">"Deep neck space infections in adults"</a> and  <a class="medical medical_review" href="/d/html/3416.html" rel="external">"Complications, diagnosis, and treatment of odontogenic infections"</a>.)</p><p class="headingAnchor" id="H19"><span class="h2">Strychnine poisoning due to ingestion of rat poison</span><span class="headingEndMark"> — </span>Accidental or intentional strychnine poisoning may produce a clinical syndrome similar to tetanus. Supportive care for both conditions is critical; thus, the initial treatment of both conditions is identical. Assays of blood, urine, and tissue for strychnine can be performed in special reference laboratories. Such tests should be obtained when there is any suspicion of accidental or intentional poisoning or when a typical history of an antecedent injury or infection for tetanus is lacking or the patient has been adequately immunized for tetanus. (See  <a class="medical medical_review" href="/d/html/310.html" rel="external">"Strychnine poisoning"</a>.)</p><p class="headingAnchor" id="H20"><span class="h2">Malignant neuroleptic syndrome</span><span class="headingEndMark"> — </span>Patients with malignant neuroleptic syndrome can present with striking symptoms of autonomic instability and muscular rigidity. However, the presence of fever, altered mental status, and recent receipt of an agent with a propensity to cause this complication usually makes the distinction from tetanus relatively easy. (See  <a class="medical medical_review" href="/d/html/4829.html" rel="external">"Neuroleptic malignant syndrome"</a>.)</p><p class="headingAnchor" id="H21"><span class="h2">Stiff-person syndrome</span><span class="headingEndMark"> — </span>Stiff-person syndrome (SPS) is a rare neurologic disorder characterized by severe muscle rigidity. Spasms of the trunk and limbs may be precipitated by voluntary movements or auditory, tactile, or emotional stimulation, all of which can also occur in tetanus. The absence of trismus or facial spasms and rapid response to <a class="drug drug_general" data-topicid="9345" href="/d/drug information/9345.html" rel="external">diazepam</a> distinguish SPS from true tetanic spasms [<a href="#rid34">34</a>]. In addition, SPS is associated with autoantibodies against glutamic acid decarboxylase. (See  <a class="medical medical_review" href="/d/html/5131.html" rel="external">"Stiff-person syndrome"</a>.)</p><p class="headingAnchor" id="H22"><span class="h1">TREATMENT</span></p><p class="headingAnchor" id="H41569084"><span class="h2">Overview</span><span class="headingEndMark"> — </span>Treatment of tetanus is best performed in the intensive care unit in consultation with an anesthesiologist or critical care specialist trained in the management of the complications of this disease, including early and aggressive airway management. The goals of treatment include:</p><p class="bulletIndent1"><span class="glyph">●</span>Halting the toxin production</p><p class="bulletIndent1"><span class="glyph">●</span>Neutralization of the unbound toxin</p><p class="bulletIndent1"><span class="glyph">●</span>Airway management</p><p class="bulletIndent1"><span class="glyph">●</span>Control of muscle spasms</p><p class="bulletIndent1"><span class="glyph">●</span>Management of dysautonomia</p><p class="bulletIndent1"><span class="glyph">●</span>General supportive management</p><p></p><p>Unfortunately, little evidence exists to support any particular therapeutic intervention in tetanus. There are only six randomized trials reported in the literature over the past 20 years [<a href="#rid35">35</a>].</p><p class="headingAnchor" id="H23"><span class="h2">Halting toxin production</span></p><p class="headingAnchor" id="H24"><span class="h3">Wound management</span><span class="headingEndMark"> — </span>All patients with tetanus should undergo wound debridement to eradicate spores and necrotic tissue, which could lead to conditions ideal for germination.</p><p class="headingAnchor" id="H25"><span class="h3">Antimicrobial therapy</span><span class="headingEndMark"> — </span>Although antibiotics probably play a relatively minor role in the management of tetanus, they are universally recommended. However, it is important to emphasize that appropriate antimicrobial therapy may fail to eradicate <em>C. tetani</em> unless adequate wound debridement is performed. This was illustrated by one study in which 45 isolates of <em>C. tetani</em> were obtained at the time of wound debridement from 84 Vietnamese patients with severe tetanus [<a href="#rid36">36</a>]. All 45 isolates were susceptible by disc diffusion and E-test to penicillin and <a class="drug drug_general" data-topicid="9646" href="/d/drug information/9646.html" rel="external">metronidazole</a>, and all were resistant to <a class="drug drug_general" data-topicid="9785" href="/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a>. However, <em>C. tetani</em> was isolated from the wounds of two patients who underwent debridement after more than two weeks of high doses of penicillin.</p><p><a class="drug drug_general" data-topicid="9646" href="/d/drug information/9646.html" rel="external">Metronidazole</a> (500 mg intravenously [IV] every six to eight hours) is the preferred treatment for tetanus, but <a class="drug drug_general" data-topicid="9749" href="/d/drug information/9749.html" rel="external">penicillin G</a> (2 to 4 million units IV every four to six hours) is a safe and effective alternative [<a href="#rid13">13</a>]. We suggest a treatment duration of 7 to 10 days.</p><p>The first study to compare penicillin and <a class="drug drug_general" data-topicid="9646" href="/d/drug information/9646.html" rel="external">metronidazole</a> found a greater reduction in mortality in the metronidazole group (7 versus 24 percent) [<a href="#rid37">37</a>]. However, in three subsequent studies, there was no difference in mortality in patients treated with penicillin and those treated with metronidazole [<a href="#rid38">38-40</a>]. In one of the former studies, patients receiving metronidazole required fewer muscle relaxants and sedatives [<a href="#rid38">38</a>]. It is possible that the observed difference in outcomes may not be due to differences in the antimicrobial activity of the two agents but rather may be explained by the GABA antagonist effect of penicillins and third-generation cephalosporins, which may lead to central nervous system (CNS) excitability.</p><p>If a mixed infection is suspected, a first-, second-, or third-generation cephalosporin such as <a class="drug drug_general" data-topicid="9214" href="/d/drug information/9214.html" rel="external">cefazolin</a> (1 to 2 g IV every 8 hours), <a class="drug drug_general" data-topicid="9230" href="/d/drug information/9230.html" rel="external">cefuroxime</a> (2 g IV every 6 hours), or <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a> (1 to 2 g IV every 24 hours) can be used.</p><p>An alternative agent is <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a> (100 mg every 12 hours); other agents with activity against <em>C. tetani</em> are macrolides, <a class="drug drug_general" data-topicid="9275" href="/d/drug information/9275.html" rel="external">clindamycin</a>, <a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">vancomycin</a>, and <a class="drug drug_general" data-topicid="9241" href="/d/drug information/9241.html" rel="external">chloramphenicol</a> [<a href="#rid13">13,41</a>]. The efficacy of these agents has not been evaluated but, based upon in vitro susceptibility data, it is likely that they are effective.</p><p class="headingAnchor" id="H26"><span class="h2">Neutralization of unbound toxin</span><span class="headingEndMark"> — </span>Since tetanus toxin is irreversibly bound to tissues, only unbound toxin is available for neutralization. The use of passive immunization (ie, antitoxin) to neutralize unbound toxin is associated with improved survival and it is considered to be standard of care [<a href="#rid42">42</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Intramuscular antitoxin</strong> – Human <a class="drug drug_general" data-topicid="9983" href="/d/drug information/9983.html" rel="external">tetanus immune globulin</a> (HTIG) is the antitoxin of choice to neutralize unbound toxin. The United States Centers for Disease Control and Prevention (CDC) recommends a single dose of 500 units intramuscularly (IM) [<a href="#rid43">43,44</a>]. The previously recommended dose range was 3000 to 6000 units. </p><p></p><p class="bulletIndent1">HTIG should be administered as soon as the diagnosis of tetanus is considered, with part of the dose infiltrated around the wound [<a href="#rid43">43,44</a>]. HTIG should be administered at different sites than tetanus toxoid. (See <a class="local">'Active immunization'</a> below.)</p><p></p><p class="bulletIndent1">If HTIG is not available intramuscular or intravenous equine antitoxin is a reasonable alternative. In a blinded, randomized trial of 215 adults with tetanus in Vietnam that compared intramuscular equine antitoxin (21,000 international units) with HTIG (3000 international units), there were no differences in mechanical ventilation rate, hospital/intensive care unit (ICU) length of stay, mortality, or adverse events [<a href="#rid45">45</a>]. If neither HTIG nor equine antitoxin is available, intravenous <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">immune globulin</a> may be administered. </p><p></p><p class="bulletIndent1">When equine antitoxin is used, an intradermal test dose of 0.1 mL in a 1:10 dilution should be administered prior to giving the full dose in order to evaluate for hypersensitivity reactions [<a href="#rid13">13</a>]. In contrast, antecedent skin testing is not needed if a human preparation is to be used.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Role of intrathecal antitoxin</strong> – In general, there is no role for intrathecal antitoxin in addition to IM antitoxin since intrathecal therapy is of unclear benefit. As an example, in the trial of 215 patients from Vietnam described above, the rate of mechanical ventilation among those who received intrathecal antitoxin in addition to IM antitoxin was similar to those who received IM antitoxin alone (43 versus 50 percent, respectively; relative risk 0.87, 95% CI 0.66 to 1.13) [<a href="#rid45">45</a>]. In another trial of 120 patients from Brazil evaluating the use of intrathecal immunoglobulin in addition to intramuscular therapy, patients receiving intrathecal therapy had a shorter duration of spasms, shorter hospital stay, and a decreased requirement for respiratory assistance; however, mortality was not significantly affected [<a href="#rid46">46</a>]. </p><p></p><p class="headingAnchor" id="H27"><span class="h2">Active immunization</span><span class="headingEndMark"> — </span>Since tetanus is one of the few bacterial diseases that does not confer immunity following recovery from acute illness, <strong>all</strong> patients with tetanus should receive active immunization with a full series (eg, three doses in adults and children &gt;7 years old) of tetanus and diphtheria toxoid-containing vaccines, commencing immediately upon diagnosis. Such vaccines should be administered at a different site than <a class="drug drug_general" data-topicid="9983" href="/d/drug information/9983.html" rel="external">tetanus immune globulin</a>. Specific recommendations on vaccine formulations and vaccination schedules are discussed in detail separately: </p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3897.html" rel="external">"Tetanus-diphtheria toxoid vaccination in adults", section on 'Routine adult immunization'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/442.html" rel="external">"Immunizations during pregnancy", section on 'Tetanus, diphtheria, and pertussis vaccination'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2844.html" rel="external">"Diphtheria, tetanus, and pertussis immunization in children 6 weeks through 6 years of age", section on 'Schedules'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2838.html" rel="external">"Diphtheria, tetanus, and pertussis immunization in children 7 through 18 years of age", section on 'Schedule'</a>.) </p><p></p><p>Subsequent tetanus doses, in the form of tetanus and diphtheria toxoid or tetanus, diphtheria, acellular pertussis, are recommended at 10-year intervals throughout adulthood in many countries including the United States [<a href="#rid47">47,48</a>]. Tetanus toxoid alone should be given only to those patients with documented allergy or untoward reactions to diphtheria toxoid. (See  <a class="medical medical_review" href="/d/html/3897.html" rel="external">"Tetanus-diphtheria toxoid vaccination in adults"</a>.)</p><p class="headingAnchor" id="H28"><span class="h2">Control of muscle spasms</span><span class="headingEndMark"> — </span>Generalized muscle spasms are life threatening since they can cause respiratory failure, lead to aspiration, and induce generalized exhaustion in the patient. Several drugs may be used to control these spasms. Attention to placement of the patient and control of light or noise in the room in an effort to avoid provoking muscle spasms was an important component of care for patients with tetanus in the past before the availability of drugs to prevent spasms. These measures are still vital in regions where the availability of neuromuscular blocking agents may be limited [<a href="#rid13">13</a>].</p><p class="headingAnchor" id="H29"><span class="h3">Benzodiazepines and other sedatives</span><span class="headingEndMark"> — </span>Benzodiazepines have been used traditionally and are generally effective in controlling the rigidity and spasms associated with tetanus [<a href="#rid13">13</a>]. They also provide a sedative effect. <a class="drug drug_general" data-topicid="9345" href="/d/drug information/9345.html" rel="external">Diazepam</a> has been used most frequently, but other benzodiazepines are as effective as diazepam. </p><p>For tetanus, the usual starting dose of <a class="drug drug_general" data-topicid="9345" href="/d/drug information/9345.html" rel="external">diazepam</a> for an adult is 10 to 30 mg IV and repeated as needed every 1 to 4 hours. When higher doses of the IV formulation of diazepam are used, the vehicle, propylene glycol, may produce hyperosmolarity and an anion gap metabolic (lactic) acidosis [<a href="#rid49">49</a>]. These abnormalities are often accompanied by acute kidney injury and can progress to multisystem organ failure. To avoid these problems when high doses of a benzodiazepine are required, a continuous infusion of IV <a class="drug drug_general" data-topicid="9650" href="/d/drug information/9650.html" rel="external">midazolam</a> can be given as it does not contain propylene glycol. Patients with tetanus often show tolerance to the sedating effects of benzodiazepines and may remain awake and alert after receiving doses that would sedate or cause anesthesia in other patients [<a href="#rid27">27</a>].</p><p>Since these drugs may be required for a prolonged period of time (often weeks), they should be tapered gradually to avoid withdrawal reactions.</p><p>The properties, usual dosing regimens for sedation, and adverse effects of benzodiazepines are discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/1616.html" rel="external">"Sedative-analgesia in ventilated adults: Medication properties, dose regimens, and adverse effects", section on 'Benzodiazepines'</a> and  <a class="medical medical_review" href="/d/html/1616.html" rel="external">"Sedative-analgesia in ventilated adults: Medication properties, dose regimens, and adverse effects", section on 'Dosing and administration'</a> and  <a class="medical medical_review" href="/d/html/1616.html" rel="external">"Sedative-analgesia in ventilated adults: Medication properties, dose regimens, and adverse effects", section on 'Propylene glycol toxicity'</a>.)</p><p>Infusion of the anesthetic <a class="drug drug_general" data-topicid="9826" href="/d/drug information/9826.html" rel="external">propofol</a> may also control spasms and rigidity. Its prolonged use has been associated with lactic acidosis, hypertriglyceridemia, and pancreatic dysfunction.</p><p class="headingAnchor" id="H30"><span class="h3">Neuromuscular blocking agents</span><span class="headingEndMark"> — </span>Neuromuscular blocking agents are used when sedation alone is inadequate. Options depend on availability. <a class="drug drug_general" data-topicid="10041" href="/d/drug information/10041.html" rel="external">Vecuronium</a> or other cardiovascularly inert neuromuscular blockers are preferred. <a class="drug drug_general" data-topicid="9738" href="/d/drug information/9738.html" rel="external">Pancuronium</a>, a long-acting agent, has been traditionally used, but it may worsen autonomic instability because it is an inhibitor of catecholamine reuptake. Neuromuscular blocking agents are generally given as continuous infusions. Monitoring of patients on these drugs is extremely important to avoid or recognize complications.</p><p><a class="drug drug_general" data-topicid="9062" href="/d/drug information/9062.html" rel="external">Baclofen</a>, which stimulates postsynaptic GABA beta receptors, has been used in a few small studies. The preferred route is intrathecal, and it may be given either in a bolus of 1000 mcg or by continuous intrathecal infusion [<a href="#rid50">50</a>]. Intrathecal baclofen given as an initial bolus in a dose ranging from 40 to 200 mcg followed by a continuous infusion of 20 mcg/hour was found to control spasms and rigidity in 21 out of 22 patients with grade III tetanus in a retrospective outcome study from a single medical center in Portugal. One of 22 patients developed meningitis secondary to infection of the intrathecal catheter despite the fact that most patients required such therapy for at least three weeks (range 8 to 30 days) [<a href="#rid51">51</a>]. In some cases, baclofen has been used without the need for mechanical ventilation [<a href="#rid52">52</a>]. Phenothiazines and barbiturates were used in the past to control spasms but have largely been displaced by neuromuscular blocking agents.</p><p class="headingAnchor" id="H31"><span class="h2">Management of autonomic dysfunction</span><span class="headingEndMark"> — </span>Several drugs have been used to produce adrenergic blockade and suppress autonomic hyperactivity; only treatment with <a class="drug drug_general" data-topicid="9585" href="/d/drug information/9585.html" rel="external">magnesium sulfate</a> has been studied in a randomized clinical trial in tetanus [<a href="#rid53">53</a>] because of its use in clinical series for the management of autonomic dysfunction and as adjunctive treatment for controlling spasms [<a href="#rid53">53-56</a>].</p><p class="headingAnchor" id="H32"><span class="h3">Magnesium sulfate</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9585" href="/d/drug information/9585.html" rel="external">Magnesium sulfate</a> acts as a presynaptic neuromuscular blocker, blocks catecholamine release from nerves, and reduces receptor responsiveness to catecholamines [<a href="#rid57">57</a>]. It has the advantage of worldwide experience in the treatment of eclampsia.</p><p>In a randomized, double blind trial in 256 hospitalized patients with severe tetanus in Vietnam, <a class="drug drug_general" data-topicid="9585" href="/d/drug information/9585.html" rel="external">magnesium sulfate</a> infusion compared with placebo controlled autonomic dysfunction [<a href="#rid53">53</a>]. The patients were randomly assigned to magnesium sulfate (loading dose 40 mg/kg over 30 minutes, followed by continuous infusion of either 2 g per hour for patients over 45 kg or 1.5 g per hour for patients ≤45 kg) versus placebo (5 percent glucose in water) infusion. Magnesium infusion significantly reduced the requirement for other drugs to control muscle spasms, and patients treated with magnesium were 4.7 times (95% CI 1.4 to 15.9) less likely to require <a class="drug drug_general" data-topicid="10043" href="/d/drug information/10043.html" rel="external">verapamil</a> to treat cardiovascular instability than those in the placebo group. Magnesium sulfate infusion did not reduce the need for mechanical ventilation. </p><p>Magnesium may also have the benefit of reducing muscle spasm. In two small unblinded trials, <a class="drug drug_general" data-topicid="9585" href="/d/drug information/9585.html" rel="external">magnesium sulfate</a> infusion (with infusion rate titrated against patella reflex) reduced spasm compared with <a class="drug drug_general" data-topicid="9345" href="/d/drug information/9345.html" rel="external">diazepam</a> [<a href="#rid58">58,59</a>].</p><p class="headingAnchor" id="H33"><span class="h3">Beta blockade</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9540" href="/d/drug information/9540.html" rel="external">Labetalol</a> (0.25 to 1 mg/min) has frequently been administered because of its dual alpha- and beta-blocking properties. Beta blockade alone with <a class="drug drug_general" data-topicid="9829" href="/d/drug information/9829.html" rel="external">propranolol</a>, for example, should be avoided because of reports of sudden death [<a href="#rid60">60</a>]. <a class="drug drug_general" data-topicid="9788" href="/d/drug information/9788.html" rel="external">Morphine</a> sulfate (0.5 to 1 mg/kg per hour by continuous intravenous infusion) is commonly used to control autonomic dysfunction as well as to induce sedation.</p><p class="headingAnchor" id="H34"><span class="h3">Other drugs</span><span class="headingEndMark"> — </span>Other drugs for the treatment of various autonomic events, which have been reported to be useful, are <a class="drug drug_general" data-topicid="8897" href="/d/drug information/8897.html" rel="external">dexmedetomidine</a>, <a class="drug drug_general" data-topicid="8983" href="/d/drug information/8983.html" rel="external">atropine</a>, <a class="drug drug_general" data-topicid="9285" href="/d/drug information/9285.html" rel="external">clonidine</a>, and epidural <a class="drug drug_general" data-topicid="9169" href="/d/drug information/9169.html" rel="external">bupivacaine</a>.</p><p class="headingAnchor" id="H35"><span class="h2">Airway management and other supportive measures</span><span class="headingEndMark"> — </span>Since tetanus toxin cannot be displaced from the nervous system once bound to neurons, supportive care is the main treatment for tetanus. In patients with severe tetanus, prolonged immobility in the intensive care unit is common, much of which is on mechanical ventilation and may last for weeks. Such patients are predisposed to nosocomial infections, decubitus ulcers, tracheal stenosis, gastrointestinal hemorrhage, and thromboembolic disease.</p><p>Endotracheal intubation is justified initially, but early tracheostomy is frequently indicated because of the likelihood of prolonged mechanical ventilation. The latter allows better tracheal suctioning and pulmonary toilet.</p><p>Energy demands in tetanus may be extremely high, so early nutritional support is mandatory. Enteral feeding is preferred. Prophylactic treatment with <a class="drug drug_general" data-topicid="9953" href="/d/drug information/9953.html" rel="external">sucralfate</a> or acid blockers may be used to prevent gastroesophageal hemorrhage from stress ulceration.</p><p>Prophylaxis of thromboembolism with heparin, low molecular weight heparin, or other anticoagulants should be administered early.</p><p>Physical therapy should be started as soon as spasms have ceased, since tetanus patients often are left with disability from prolonged muscle wasting and contractures [<a href="#rid61">61</a>].</p><p class="headingAnchor" id="H435843195"><span class="h2">Considerations in resource-limited settings</span><span class="headingEndMark"> — </span>Critical care services are often unavailable or rudimentary in many resource-limited countries [<a href="#rid13">13</a>]. When ICUs are not available, acute respiratory failure is a leading cause of death from tetanus. In the absence of an ICU, ideally a separate ward or room should be designated for patients with tetanus, and sensory stimuli should be kept to a minimum since loud noises, physical contact, and light can trigger tetanic spasms [<a href="#rid13">13</a>]. Other options include eye shades and ear plugs to reduce stimuli. Nondepolarizing paralytic agents, such as <a class="drug drug_general" data-topicid="10041" href="/d/drug information/10041.html" rel="external">vecuronium</a> and <a class="drug drug_general" data-topicid="9738" href="/d/drug information/9738.html" rel="external">pancuronium</a>, are not safe to use in the absence of ventilatory support. However, benzodiazepines and <a class="drug drug_general" data-topicid="9062" href="/d/drug information/9062.html" rel="external">baclofen</a> can be used in such situations if doses are carefully titrated to avoid respiratory depression. <a class="drug drug_general" data-topicid="9585" href="/d/drug information/9585.html" rel="external">Magnesium sulfate</a> may be used to manage autonomic dysfunction and as an adjunctive for muscle spasm. (See <a class="local">'Control of muscle spasms'</a> above and <a class="local">'Magnesium sulfate'</a> above.)</p><p class="headingAnchor" id="H1917252"><span class="h1">PROPHYLAXIS</span><span class="headingEndMark"> — </span>Tetanus prophylaxis following a puncture wound is discussed in detail separately. The following table summarizes the approach to tetanus prophylaxis (<a class="graphic graphic_table graphicRef61087" href="/d/graphic/61087.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/d/html/7661.html" rel="external">"Infectious complications of puncture wounds", section on 'Tetanus immunization'</a>.)</p><p>Immunization of women who are pregnant or of childbearing age reduces neonatal tetanus mortality by approximately 94 percent [<a href="#rid24">24</a>]. Improving hygiene during home births in resource-limited settings is also likely to play an important role in preventing neonatal tetanus.</p><p class="headingAnchor" id="H36"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>Case-fatality rates for non-neonatal tetanus in resource-limited countries range from 5 to 50 percent [<a href="#rid24">24,32,61</a>], whereas the majority of patients with tetanus recover when modern supportive care is available [<a href="#rid62">62</a>]. Long-term functional outcome in adult survivors can be impaired, particularly in older adults [<a href="#rid61">61,63,64</a>]. In Japan, 290 out of 465 survivors of tetanus were discharged home and the remainder to other facilities [<a href="#rid64">64</a>]. In France, only 61.5 percent of 70 patients surviving an intensive care unit stay for tetanus were reported to have no functional disability [<a href="#rid63">63</a>].</p><p>Neonatal tetanus, once nearly always fatal, now has mortality rates of 3 to 88 percent [<a href="#rid24">24</a>]. Patients with shorter incubation periods (eg, ≤7 days) have increased disease severity and mortality [<a href="#rid24">24,65</a>].</p><p>Among neonatal infections, survivors may recover fully or have varying degrees of neurologic damage ranging from minor intellectual deficits to cerebral palsy [<a href="#rid66">66</a>]. </p><p class="headingAnchor" id="H3078921681"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/113042.html" rel="external">"Society guideline links: Tetanus infection"</a>.)</p><p class="headingAnchor" id="H183590090"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/d/html/83176.html" rel="external">"Patient education: Tetanus (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H37"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology</strong> – Although rare, tetanus remains a threat to all unvaccinated people, particularly in resource-limited countries. Since <em>Clostridium tetani</em> spores cannot be eliminated from the environment, immunization and proper treatment of wounds and traumatic injuries are crucial for tetanus prevention. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features/diagnosis</strong> – Tetanus is a clinical diagnosis and should be considered in patients with an inadequate vaccination history and consistent clinical findings. The most common and severe clinical form of tetanus is generalized tetanus. The presenting symptom in more than 80 percent of such patients is trismus (lockjaw), although patients with generalized tetanus sometimes present initially with cephalic (involving the cranial nerves) or localized tetanus. (See <a class="local">'Clinical features'</a> above and <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Supportive care</strong> – Supportive care is the mainstay of management to avoid complications such as respiratory failure, nosocomial infections, and thromboembolism. (See <a class="local">'Airway management and other supportive measures'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Halting and neutralizing toxin production</strong> – Since tetanus is mediated by a toxin, a crucial aspect of therapy is to eliminate ongoing toxin production. This includes debriding the wound and administering antimicrobial therapy (eg, <a class="drug drug_general" data-topicid="9646" href="/d/drug information/9646.html" rel="external">metronidazole</a> 500 mg intravenously every six to eight hours for 7 to 10 days). In addition, patients should receive passive immunization with antitoxin (eg, human <a class="drug drug_general" data-topicid="9983" href="/d/drug information/9983.html" rel="external">tetanus immune globulin</a>) to neutralize unbound toxin. (See <a class="local">'Halting toxin production'</a> above and <a class="local">'Neutralization of unbound toxin'</a> above.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Control of muscle spasms</strong> – Muscle spasms are controlled with sedation (usually benzodiazepines) or neuromuscular blockade. (See <a class="local">'Control of muscle spasms'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Autonomic dysfunction</strong> – Autonomic hyperactivity can be treated with <a class="drug drug_general" data-topicid="9540" href="/d/drug information/9540.html" rel="external">labetalol</a> or <a class="drug drug_general" data-topicid="9788" href="/d/drug information/9788.html" rel="external">morphine</a> sulfate. Beta blockade without concomitant alpha blockade should be avoided. </p><p></p><p class="bulletIndent2">The use of <a class="drug drug_general" data-topicid="9585" href="/d/drug information/9585.html" rel="external">magnesium sulfate</a> for both autonomic dysfunction and additional control of muscle spasms has generated considerable interest. This drug is readily available and is used worldwide for the treatment of eclampsia. (See <a class="local">'Management of autonomic dysfunction'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Active immunization</strong> – All patients with tetanus should receive active immunization with a full vaccine series (eg, three doses in adults and children &gt;7 years old) of tetanus and diphtheria toxoid-containing vaccines; tetanus is one of the few bacterial diseases that does not confer immunity following recovery from acute illness. Immunization should commence immediately upon diagnosis, and vaccines should be administered at a different site than <a class="drug drug_general" data-topicid="9983" href="/d/drug information/9983.html" rel="external">tetanus immune globulin</a>. (See <a class="local">'Active immunization'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevention</strong> – Tetanus prophylaxis following a puncture wound should be administered to those who are unvaccinated against tetanus, as well as those who were vaccinated against tetanus previously, but who are not up to date with their vaccines (<a class="graphic graphic_table graphicRef61087" href="/d/graphic/61087.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/d/html/7661.html" rel="external">"Infectious complications of puncture wounds", section on 'Tetanus immunization'</a>.)</p><p></p><p class="bulletIndent1">Immunization of women who are pregnant or of childbearing age dramatically reduces neonatal tetanus mortality. Improving hygiene during home births in resource-limited settings is also likely to play an important role in preventing neonatal tetanus. (See <a class="local">'Prophylaxis'</a> above.)</p><p></p><p class="headingAnchor" id="H911281676"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>UpToDate gratefully acknowledges John G Bartlett, MD (deceased), who contributed as Section Editor on earlier versions of this topic and was a founding Editor-in-Chief for UpToDate in Infectious Diseases.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Centers for Disease Control and Prevention. Tetanus. https://www.cdc.gov/vaccines/pubs/surv-manual/chpt16-tetanus.html (Accessed on February 24, 2020).</li><li><a class="nounderline abstract_t">Roper L, Hall MAK, Cohn A. Overview of the United States' Immunization Program. J Infect Dis 2021; 224:S443.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Tetanus surveillance --- United States, 2001-2008. MMWR Morb Mortal Wkly Rep 2011; 60:365.</a></li><li><a class="nounderline abstract_t">Yen C, Murray E, Zipprich J, et al. Missed opportunities for tetanus postexposure prophylaxis--California, January 2008-March 2014. MMWR Morb Mortal Wkly Rep 2015; 64:243.</a></li><li><a class="nounderline abstract_t">Yaffee AQ, Day DL, Bastin G, et al. Notes from the Field: Obstetric Tetanus in an Unvaccinated Woman After a Home Birth Delivery - Kentucky, 2016. MMWR Morb Mortal Wkly Rep 2017; 66:307.</a></li><li><a class="nounderline abstract_t">Berger SA, Cherubin CE, Nelson S, Levine L. Tetanus despite preexisting antitetanus antibody. JAMA 1978; 240:769.</a></li><li><a class="nounderline abstract_t">Rushdy AA, White JM, Ramsay ME, Crowcroft NS. Tetanus in England and Wales, 1984-2000. Epidemiol Infect 2003; 130:71.</a></li><li class="breakAll">Public Health England. Tetanus in England: 2018. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/788744/hpr1019_ttns.pdf (Accessed on February 24, 2020).</li><li><a class="nounderline abstract_t">Collins S, Amirthalingam G, Beeching NJ, et al. Current epidemiology of tetanus in England, 2001-2014. Epidemiol Infect 2016; 144:3343.</a></li><li class="breakAll">Annual Epidemiological Report for 2018 - Tetanus. European Centre for Disease Prevention and Control. Available at: https://www.ecdc.europa.eu/sites/default/files/documents/Tetanus_AER_2018_Report.pdf. (Accessed on May 13, 2022).</li><li><a class="nounderline abstract_t">McQuillan GM, Kruszon-Moran D, Deforest A, et al. Serologic immunity to diphtheria and tetanus in the United States. Ann Intern Med 2002; 136:660.</a></li><li><a class="nounderline abstract_t">Gergen PJ, McQuillan GM, Kiely M, et al. A population-based serologic survey of immunity to tetanus in the United States. N Engl J Med 1995; 332:761.</a></li><li><a class="nounderline abstract_t">Afshar M, Raju M, Ansell D, Bleck TP. Narrative review: tetanus-a health threat after natural disasters in developing countries. Ann Intern Med 2011; 154:329.</a></li><li><a class="nounderline abstract_t">Kyu HH, Mumford JE, Stanaway JD, et al. Mortality from tetanus between 1990 and 2015: findings from the global burden of disease study 2015. BMC Public Health 2017; 17:179.</a></li><li><a class="nounderline abstract_t">Nanteza B, Galukande M, Aceng J, et al. The burden of tetanus in Uganda. Springerplus 2016; 5:705.</a></li><li><a class="nounderline abstract_t">Woldeamanuel YW, Andemeskel AT, Kyei K, et al. Case fatality of adult tetanus in Africa: Systematic review and meta-analysis. J Neurol Sci 2016; 368:292.</a></li><li class="breakAll">World Health Organization. Immunization surveillance, assessment and monitoring. Maternal and Neonatal Tetanus (MNT) elimination. http://www.who.int/immunization_monitoring/diseases/MNTE_initiative/en/index.html (Accessed on March 14, 2011).</li><li><a class="nounderline abstract_t">Lalli G, Bohnert S, Deinhardt K, et al. The journey of tetanus and botulinum neurotoxins in neurons. Trends Microbiol 2003; 11:431.</a></li><li><a class="nounderline abstract_t">Deinhardt K, Berninghausen O, Willison HJ, et al. Tetanus toxin is internalized by a sequential clathrin-dependent mechanism initiated within lipid microdomains and independent of epsin1. J Cell Biol 2006; 174:459.</a></li><li><a class="nounderline abstract_t">Schiavo G, Benfenati F, Poulain B, et al. Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin. Nature 1992; 359:832.</a></li><li><a class="nounderline abstract_t">Caccin P, Rossetto O, Rigoni M, et al. VAMP/synaptobrevin cleavage by tetanus and botulinum neurotoxins is strongly enhanced by acidic liposomes. FEBS Lett 2003; 542:132.</a></li><li><a class="nounderline abstract_t">Farrar JJ, Yen LM, Cook T, et al. Tetanus. J Neurol Neurosurg Psychiatry 2000; 69:292.</a></li><li><a class="nounderline abstract_t">Rummel A, Bade S, Alves J, et al. Two carbohydrate binding sites in the H(CC)-domain of tetanus neurotoxin are required for toxicity. J Mol Biol 2003; 326:835.</a></li><li><a class="nounderline abstract_t">Thwaites CL, Beeching NJ, Newton CR. Maternal and neonatal tetanus. Lancet 2015; 385:362.</a></li><li><a class="nounderline abstract_t">Grund JM, Toledo C, Davis SM, et al. Notes from the Field: Tetanus Cases After Voluntary Medical Male Circumcision for HIV Prevention--Eastern and Southern Africa, 2012-2015. MMWR Morb Mortal Wkly Rep 2016; 65:36.</a></li><li><a class="nounderline abstract_t">Gonzales y Tucker RD, Frazee B. View from the front lines: an emergency medicine perspective on clostridial infections in injection drug users. Anaerobe 2014; 30:108.</a></li><li><a class="nounderline abstract_t">Ergonul O, Egeli D, Kahyaoglu B, et al. An unexpected tetanus case. Lancet Infect Dis 2016; 16:746.</a></li><li class="breakAll">Centers for Disease Control and Prevention. Epidemiology and Prevention of Vaccine-Preventable Diseases. Tetanus. https://www.cdc.gov/vaccines/pubs/pinkbook/tetanus.html (Accessed on September 06, 2017).</li><li><a class="nounderline abstract_t">Doshi A, Warrell C, Dahdaleh D, Kullmann D. Just a graze? Cephalic tetanus presenting as a stroke mimic. Pract Neurol 2014; 14:39.</a></li><li><a class="nounderline abstract_t">Weinstein L. Tetanus. N Engl J Med 1973; 289:1293.</a></li><li><a class="nounderline abstract_t">Idema CD, Harris BN, Ogunbanjo GA, Dürrheim DN. Neonatal tetanus elimination in Mpumalanga Province, South Africa. Trop Med Int Health 2002; 7:622.</a></li><li><a class="nounderline abstract_t">Roper MH, Vandelaer JH, Gasse FL. Maternal and neonatal tetanus. Lancet 2007; 370:1947.</a></li><li><a class="nounderline abstract_t">Thwaites CL, Yen LM, Glover C, et al. Predicting the clinical outcome of tetanus: the tetanus severity score. Trop Med Int Health 2006; 11:279.</a></li><li><a class="nounderline abstract_t">Andreadou E, Kattoulas E, Sfagos C, Vassilopoulos D. Stiff person syndrome: avoiding misdiagnosis. Neurol Sci 2007; 28:35.</a></li><li><a class="nounderline abstract_t">Rodrigo C, Fernando D, Rajapakse S. Pharmacological management of tetanus: an evidence-based review. Crit Care 2014; 18:217.</a></li><li><a class="nounderline abstract_t">Campbell JI, Lam TM, Huynh TL, et al. Microbiologic characterization and antimicrobial susceptibility of Clostridium tetani isolated from wounds of patients with clinically diagnosed tetanus. Am J Trop Med Hyg 2009; 80:827.</a></li><li><a class="nounderline abstract_t">Ahmadsyah I, Salim A. Treatment of tetanus: an open study to compare the efficacy of procaine penicillin and metronidazole. Br Med J (Clin Res Ed) 1985; 291:648.</a></li><li class="breakAll">Yen LM, Dao LM, Day NPJ. Management of tetanus: a comparison of penicillin and metronidazole. Symposium of antimicrobial resistance in southern Viet Nam, 1997.</li><li><a class="nounderline abstract_t">Saltoglu N, Tasova Y, Midikli D, et al. Prognostic factors affecting deaths from adult tetanus. Clin Microbiol Infect 2004; 10:229.</a></li><li><a class="nounderline abstract_t">Ganesh Kumar AV, Kothari VM, Krishnan A, Karnad DR. Benzathine penicillin, metronidazole and benzyl penicillin in the treatment of tetanus: a randomized, controlled trial. Ann Trop Med Parasitol 2004; 98:59.</a></li><li class="breakAll">Johnson EA, Summanen P, Finegold SM. Clostridium. In: Manual of Clinical Microbiology, 9th edition, Murray PR, Baron EJ, Jorgensen JH, et al (Eds), ASM Press, Washington DC 2007. Vol 1, p.889.</li><li><a class="nounderline abstract_t">Vakil BJ, Tulpule TH, Armitage P, Laurence DR. A comparison of the value of 200,000 I.U. of tetanus antitoxin (horse) with 10,000 I.U. in the treatment of tetanus. Clin Pharmacol Ther 1968; 9:465.</a></li><li class="breakAll">American Academy of Pediatrics. Tetanus (lockjaw). In: Red Book: 2009 Report of the Committee on Infectious Diseases, 28th, American Academy of Pediatrics, Elk Grove Village, IL 2009. p.655.</li><li class="breakAll">Centers for Disease Control and Prevention. Tetanus - Wound Management. https://www.cdc.gov/vaccines/pubs/pinkbook/tetanus.html#medical (Accessed on February 24, 2020).</li><li><a class="nounderline abstract_t">Van Hao N, Loan HT, Yen LM, et al. Human versus equine intramuscular antitoxin, with or without human intrathecal antitoxin, for the treatment of adults with tetanus: a 2 × 2 factorial randomised controlled trial. Lancet Glob Health 2022; 10:e862.</a></li><li><a class="nounderline abstract_t">Miranda-Filho Dde B, Ximenes RA, Barone AA, et al. Randomised controlled trial of tetanus treatment with antitetanus immunoglobulin by the intrathecal or intramuscular route. BMJ 2004; 328:615.</a></li><li><a class="nounderline abstract_t">Liang JL, Tiwari T, Moro P, et al. Prevention of Pertussis, Tetanus, and Diphtheria with Vaccines in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2018; 67:1.</a></li><li><a class="nounderline abstract_t">Havers FP, Moro PL, Hunter P, et al. Use of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccines: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2019. MMWR Morb Mortal Wkly Rep 2020; 69:77.</a></li><li><a class="nounderline abstract_t">Kapoor W, Carey P, Karpf M. Induction of lactic acidosis with intravenous diazepam in a patient with tetanus. Arch Intern Med 1981; 141:944.</a></li><li><a class="nounderline abstract_t">Engrand N, Guerot E, Rouamba A, Vilain G. The efficacy of intrathecal baclofen in severe tetanus. Anesthesiology 1999; 90:1773.</a></li><li><a class="nounderline abstract_t">Santos ML, Mota-Miranda A, Alves-Pereira A, et al. Intrathecal baclofen for the treatment of tetanus. Clin Infect Dis 2004; 38:321.</a></li><li><a class="nounderline abstract_t">Engrand N, Vilain G, Rouamba A, Benhamou D. [Value of intrathecal baclofen in the treatment of severe tetanus in the tropical milieu]. Med Trop (Mars) 2000; 60:385.</a></li><li><a class="nounderline abstract_t">Thwaites CL, Yen LM, Loan HT, et al. Magnesium sulphate for treatment of severe tetanus: a randomised controlled trial. Lancet 2006; 368:1436.</a></li><li><a class="nounderline abstract_t">Attygalle D, Rodrigo N. Magnesium as first line therapy in the management of tetanus: a prospective study of 40 patients. Anaesthesia 2002; 57:811.</a></li><li><a class="nounderline abstract_t">James MF, Manson ED. The use of magnesium sulphate infusions in the management of very severe tetanus. Intensive Care Med 1985; 11:5.</a></li><li><a class="nounderline abstract_t">Ceneviva GD, Thomas NJ, Kees-Folts D. Magnesium sulfate for control of muscle rigidity and spasms and avoidance of mechanical ventilation in pediatric tetanus. Pediatr Crit Care Med 2003; 4:480.</a></li><li><a class="nounderline abstract_t">Lipman J, James MF, Erskine J, et al. Autonomic dysfunction in severe tetanus: magnesium sulfate as an adjunct to deep sedation. Crit Care Med 1987; 15:987.</a></li><li><a class="nounderline abstract_t">Osalusi BS, Ogun SA, Ogunniyi A, Kolapo KO. Comparison of the efficacy of magnessium sulphate. Scientific Research and Essay 2008; 3:571.</a></li><li><a class="nounderline abstract_t">Ali G, Kamal M, Khan AN. Comparison of the efficacy of magnesium sulphate and diazepam in the control of tetanus spasm. J Pak Med Assoc 2011; 25:106.</a></li><li><a class="nounderline abstract_t">Buchanan N, Smit L, Cane RD, De Andrade M. Sympathetic overactivity in tetanus: fatality associated with propranolol. Br Med J 1978; 2:254.</a></li><li><a class="nounderline abstract_t">Trung TN, Duoc NVT, Nhat LTH, et al. Functional outcome and muscle wasting in adults with tetanus. Trans R Soc Trop Med Hyg 2019; 113:706.</a></li><li><a class="nounderline abstract_t">Trujillo MH, Castillo A, España J, et al. Impact of intensive care management on the prognosis of tetanus. Analysis of 641 cases. Chest 1987; 92:63.</a></li><li><a class="nounderline abstract_t">Mahieu R, Reydel T, Maamar A, et al. Admission of tetanus patients to the ICU: a retrospective multicentre study. Ann Intensive Care 2017; 7:112.</a></li><li><a class="nounderline abstract_t">Nakajima M, Aso S, Matsui H, et al. Clinical features and outcomes of tetanus: Analysis using a National Inpatient Database in Japan. J Crit Care 2018; 44:388.</a></li><li><a class="nounderline abstract_t">Patel JC, Mehta BC. Tetanus: study of 8,697 cases. Indian J Med Sci 1999; 53:393.</a></li><li><a class="nounderline abstract_t">Barlow JL, Mung'Ala-Odera V, Gona J, Newton CR. Brain damage after neonatal tetanus in a rural Kenyan hospital. Trop Med Int Health 2001; 6:305.</a></li></ol></div><div id="topicVersionRevision">Topic 5525 Version 46.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://www.cdc.gov/vaccines/pubs/surv-manual/chpt16-tetanus.html" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Centers for Disease Control and Prevention. Tetanus. https://www.cdc.gov/vaccines/pubs/surv-manual/chpt16-tetanus.html (Accessed on February 24, 2020).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34590134" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Overview of the United States' Immunization Program.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21451446" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Tetanus surveillance --- United States, 2001-2008.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25763876" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Missed opportunities for tetanus postexposure prophylaxis--California, January 2008-March 2014.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28333909" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Notes from the Field: Obstetric Tetanus in an Unvaccinated Woman After a Home Birth Delivery - Kentucky, 2016.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/671711" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Tetanus despite preexisting antitetanus antibody.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12613747" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Tetanus in England and Wales, 1984-2000.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12613747" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Tetanus in England and Wales, 1984-2000.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27535200" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Current epidemiology of tetanus in England, 2001-2014.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27535200" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Current epidemiology of tetanus in England, 2001-2014.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11992301" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Serologic immunity to diphtheria and tetanus in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7862178" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : A population-based serologic survey of immunity to tetanus in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21357910" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Narrative review: tetanus-a health threat after natural disasters in developing countries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28178973" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Mortality from tetanus between 1990 and 2015: findings from the global burden of disease study 2015.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27350934" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : The burden of tetanus in Uganda.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27538652" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Case fatality of adult tetanus in Africa: Systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27538652" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Case fatality of adult tetanus in Africa: Systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13678859" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : The journey of tetanus and botulinum neurotoxins in neurons.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16880274" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Tetanus toxin is internalized by a sequential clathrin-dependent mechanism initiated within lipid microdomains and independent of epsin1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1331807" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12729912" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : VAMP/synaptobrevin cleavage by tetanus and botulinum neurotoxins is strongly enhanced by acidic liposomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10945801" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Tetanus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12581644" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Two carbohydrate binding sites in the H(CC)-domain of tetanus neurotoxin are required for toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25149223" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Maternal and neonatal tetanus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26797167" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Notes from the Field: Tetanus Cases After Voluntary Medical Male Circumcision for HIV Prevention--Eastern and Southern Africa, 2012-2015.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25230330" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : View from the front lines: an emergency medicine perspective on clostridial infections in injection drug users.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27301930" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : An unexpected tetanus case.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27301930" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : An unexpected tetanus case.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24052566" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Just a graze? Cephalic tetanus presenting as a stroke mimic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4270702" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Tetanus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12100446" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Neonatal tetanus elimination in Mpumalanga Province, South Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17854885" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Maternal and neonatal tetanus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16553907" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Predicting the clinical outcome of tetanus: the tetanus severity score.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17385093" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Stiff person syndrome: avoiding misdiagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25029486" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Pharmacological management of tetanus: an evidence-based review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19407132" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Microbiologic characterization and antimicrobial susceptibility of Clostridium tetani isolated from wounds of patients with clinically diagnosed tetanus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3928066" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Treatment of tetanus: an open study to compare the efficacy of procaine penicillin and metronidazole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3928066" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Treatment of tetanus: an open study to compare the efficacy of procaine penicillin and metronidazole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15008944" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Prognostic factors affecting deaths from adult tetanus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15000732" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Benzathine penicillin, metronidazole and benzyl penicillin in the treatment of tetanus: a randomized, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15000732" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Benzathine penicillin, metronidazole and benzyl penicillin in the treatment of tetanus: a randomized, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4871900" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : A comparison of the value of 200,000 I.U. of tetanus antitoxin (horse) with 10,000 I.U. in the treatment of tetanus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4871900" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : A comparison of the value of 200,000 I.U. of tetanus antitoxin (horse) with 10,000 I.U. in the treatment of tetanus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4871900" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : A comparison of the value of 200,000 I.U. of tetanus antitoxin (horse) with 10,000 I.U. in the treatment of tetanus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35561721" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Human versus equine intramuscular antitoxin, with or without human intrathecal antitoxin, for the treatment of adults with tetanus: a 2 × 2 factorial randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15003976" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Randomised controlled trial of tetanus treatment with antitetanus immunoglobulin by the intrathecal or intramuscular route.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29702631" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Prevention of Pertussis, Tetanus, and Diphtheria with Vaccines in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31971933" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Use of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccines: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2019.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7235819" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Induction of lactic acidosis with intravenous diazepam in a patient with tetanus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10360878" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : The efficacy of intrathecal baclofen in severe tetanus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14727200" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Intrathecal baclofen for the treatment of tetanus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11436597" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : [Value of intrathecal baclofen in the treatment of severe tetanus in the tropical milieu].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17055945" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Magnesium sulphate for treatment of severe tetanus: a randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12133096" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Magnesium as first line therapy in the management of tetanus: a prospective study of 40 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3968303" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : The use of magnesium sulphate infusions in the management of very severe tetanus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14525647" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Magnesium sulfate for control of muscle rigidity and spasms and avoidance of mechanical ventilation in pediatric tetanus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3652717" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Autonomic dysfunction in severe tetanus: magnesium sulfate as an adjunct to deep sedation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Comparison of the efficacy of magnessium sulphate</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Comparison of the efficacy of magnesium sulphate and diazepam in the control of tetanus spasm</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/678897" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Sympathetic overactivity in tetanus: fatality associated with propranolol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31340037" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Functional outcome and muscle wasting in adults with tetanus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3595250" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Impact of intensive care management on the prognosis of tetanus. Analysis of 641 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29116572" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Admission of tetanus patients to the ICU: a retrospective multicentre study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29304489" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Clinical features and outcomes of tetanus: Analysis using a National Inpatient Database in Japan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10710833" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Tetanus: study of 8,697 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11348521" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Brain damage after neonatal tetanus in a rural Kenyan hospital.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
